🔗 Share this article

Chancellor Rachel Reeves has stated she is preparing "specific measures to address cost of living pressures" in next month's Budget.

Speaking to media outlets, she stated that curbing price rises is a shared responsibility of both the administration and the Bank of England.

The United Kingdom's inflation rate is forecast to be the most elevated among the G7 advanced economies this year and the following year.

Potential Utility Cost Interventions

It is understood the government could intervene to lower utility costs, such as by cutting the current 5% level of VAT charged on energy.

An additional approach is to lower some of the regulatory levies currently included in bills.

Fiscal Constraints and Analyst Expectations

The administration will obtain the latest report from the independent fiscal watchdog, the Office for Budget Responsibility, on the start of the week, which will clarify how much room there is for these measures.

The consensus from the majority of economists is that the Chancellor will have to introduce higher taxes or spending cuts in order to adhere to her voluntary debt limits.

Earlier on the same day, calculations suggested there was a £22bn shortfall for the Treasury chief to fill, which is at the lower end of forecasts.

"It is a joint job between the Bank of England and the administration to bear down further on some of the drivers of inflation," the Chancellor informed reporters in Washington, at the yearly gatherings of the IMF and global financial institution.

Revenue Commitments and International Concerns

While much of the focus has been on expected tax rises, the Treasury chief said the most recent information from the fiscal watchdog had not altered her vow to election pledges not to increase tax levels on income tax, VAT or social security contributions.

She attributed an "unpredictable world" with increasing geopolitical and trade tensions for the fiscal revenue measures, probably to be targeted on those "wealthiest."

Global Economic Tensions

Referring to apprehensions about the United Kingdom's commercial links with the Asian nation she said: "Our national security always come first."

Recent declaration by Chinese authorities to strengthen export controls on critical minerals and other materials that are crucial for high-technology manufacturing led US President the US President to threaten an additional 100% tariff on imports from the Asian country, raising the prospect of an all-out commercial conflict between the two largest economies.

The American finance chief described China's action "economic coercion" and "a global supply chain power grab."

Inquired about considering the US offer to join its dispute with the Asian nation, the Chancellor said she was "very concerned" by China's measures and encouraged the Chinese government "to avoid restrictions and restrict access."

She said the action was "damaging for the international commerce and causes further obstacles."

"It is my opinion there are fields where we need to challenge China, but there are also valuable prospects to trade with Chinese markets, including banking sector and other sectors of the economic system. We've got to maintain that balance appropriate."

The Treasury chief also affirmed she was collaborating with international partners "on our own essential resources approach, so that we are less reliant."

Health Service Medicine Pricing and Funding

The Chancellor also recognized that the price the NHS pays for drugs could go up as a result of current discussions with the Trump administration and its drugs companies, in exchange for lower tariffs and funding.

Some of the biggest global pharmaceutical manufacturers have said lately that they are either pausing or canceling projects in the United Kingdom, with several attributing the modest returns they are obtaining.

Recently, the Science Minister said the cost the health service pays for medicines would must increase to prevent companies and pharmaceutical investment departing from the UK.

The Chancellor stated to the BBC: "It has been observed as a result of the cost structure, that medical research, recent pharmaceuticals have not been offered in the UK in the extent that they are in other EU nations."

"The objective is to ensure that people getting treatment from the National Health Service are can obtain the finest essential drugs in the world. And so we are looking at this situation, and... aiming to attract additional funding into Britain."